Chemotherapy and radiotherapy: Cryptic anticancer vaccines

被引：154

作者：

Ma, Yuting ^{[2
,3
]}

Kepp, Oliver ^{[3
]}

Ghiringhelli, Francois ^{[2
,3
,4
,5
]}

Apetoh, Lionel ^{[2
,3
]}

Aymerica, Laetitia ^{[2
,3
]}

Locher, Clara ^{[2
,3
]}

Tesniere, Antoine ^{[3
]}

Martins, Isabelle ^{[3
]}

Ly, Andre ^{[2
,3
]}

Haynes, Nicole M. ^{[6
]}

Smyth, Mark J. ^{[6
]}

Kroemer, Guido ^{[1
,3
]}

Zitvogel, Laurence ^{[2
,3
]}

机构：

[1] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

[2] INSERM, U805, F-94805 Villejuif, France

[3] Univ Paris 11, F-94805 Villejuif, France

[4] INSERM, CRI 866, AVENIR Team, F-21000 Dijon, France

[5] Ctr Georges Francois Leclerc, F-21000 Dijon, France

[6] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

SEMINARS IN IMMUNOLOGY | 2010年 / 22卷 / 03期

基金：

英国医学研究理事会;

关键词：

Chemotherapy; Cancer; Inflammasome; Interleukin-1; beta; Interferon-gamma; COLONY-STIMULATING FACTOR; MEDIATED TUMOR DESTRUCTION; LOW-DOSE CYCLOPHOSPHAMIDE; ACUTE MYELOID-LEUKEMIA; AUGMENTS ANTITUMOR IMMUNITY; AUTOLOGOUS MELANOMA-CELLS; HEAT-SHOCK PROTEINS; REGULATORY T-CELLS; DENDRITIC CELLS; APOPTOTIC CELLS;

D O I：

10.1016/j.smim.2010.03.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger "danger signals" emitted from immunogenic cell death and hence elicit "danger associated molecular patterns" to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of "immunogenic chemotherapy" at the levels of the drug, of the tumor cell and of the host immune system. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：113 / 124

页数：12

共 123 条

[1] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[2] Tumor-specific killer cells in paraneoplastic cerebellar degeneration [J].

Albert, ML ;

Darnell, JC ;

Bender, A ;

Francisco, LM ;

Bhardwaj, N ;

Darnell, RB .

NATURE MEDICINE, 1998, 4 (11) :1321-1324

[3] The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Criollo, Alfredo ;

Ortiz, Carla ;

Lidereau, Rosette ;

Mariette, Christophe ;

Chaput, Nathalie ;

Mira, Jean-Paul ;

Delaloge, Suzette ;

Andre, Fabrice ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59

[4] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[5] TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].

Arbour, NC ;

Lorenz, E ;

Schutte, BC ;

Zabner, J ;

Kline, JN ;

Jones, M ;

Frees, K ;

Watt, JL ;

Schwartz, DA .

NATURE GENETICS, 2000, 25 (02) :187-+

[6] Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].

Audia, S. ;

Nicolas, A. ;

Cathelin, D. ;

Larmonier, N. ;

Ferrand, C. ;

Foucher, P. ;

Fanton, A. ;

Bergoin, E. ;

Maynadie, M. ;

Arnould, L. ;

Bateman, A. ;

Lorcerie, B. ;

Solary, E. ;

Chauffert, B. ;

Bonnotte, B. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530

[7] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[8] The extracellular release of HMGB1 during apoptotic cell death [J].

Bell, Charles W. ;

Jiang, Weiwen ;

Reich, Charles F., III ;

Pisetsky, David S. .

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2006, 291 (06) :C1318-C1325

[9] NON-H-2 RESTRICTION OF EXPRESSION OF PASSIVELY TRANSFERRED DELAYED SENSITIVITY [J].

BERCHE, PA ;

NORTH, RJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (05) :1334-1343

[10]

BERD D, 1986, CANCER RES, V46, P2572

← 1 2 3 4 5 6 7 8 9 10 →